In the management of thalassemia, which complication is associated with regular blood transfusions and is commonly treated with iron chelation therapy?

• A. Iron overload
• B. Infection
• C. Hypertension
• D. Renal failure

Answer: (A)

Iron overload from regular blood transfusions is the complication most tied to the thalassemia management scenario. When patients receive frequent transfusions, the body accumulates iron faster than it can be excreted because there’s no natural mechanism to get rid of the excess iron. This iron builds up in organs such as the liver, heart, and endocrine glands, leading to serious problems like hepatic fibrosis, cardiomyopathy, diabetes, and hypogonadism.

Iron chelation therapy is used to remove this excess iron. Chelators like deferoxamine, deferasirox, and deferiprone bind ferric iron and help eliminate it through urine or stool, reducing the total body iron burden and protecting organ function. Monitoring often involves ferritin levels and imaging (for example, MRI T2* in the heart and liver) to gauge iron load and guide treatment duration and choice of chelator. Adherence is crucial because ongoing iron accumulation continues to cause damage over time.

Other options—such as infection, hypertension, or renal failure—can occur in individuals with thalassemia but are not the complication specifically addressed by chelation therapy. Infections relate to transfusion safety and immune status, while hypertension and renal issues have different etiologies and management approaches.